Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Metronidazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.88 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.88 |
| ▸ | THRB | P10828 | 1/20 | 0.88 |
| ▸ | TSHR | P16473 | 1/20 | 0.88 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 5/20 | 0.58 |
| ▸ | CA2 | P00918 | 5/20 | 0.58 |
| ▸ | CA9 | Q16790 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 4/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metronidazole SCHEMBL3765189 | 0.95 | LMNA (0.91) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL31108924 | 0.94 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL23042 | 0.94 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL2221140 | 0.94 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL9482744 | 0.94 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL9481347 | 0.94 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL9455119 | 0.94 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL5313560 | 0.94 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL5595814 | 0.92 | LMNA (0.97) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL8675069 | 0.92 | LMNA (0.97) | LMNAALDH1A1MAPK1THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032455-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2025-01-30 | — | — | US | disclosed |
| US-12171748-B2 | Nitroimidazole formulations | IRP Health Pty Ltd (AU) | 2024-12-24 | — | — | US | disclosed |
| CN-115785185-B | Bile acid-metronidazole conjugate and application thereof | 华南理工大学 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024120184-A1 | BILE ACID-METRONIDAZOLE CONJUGATE AND USE THEREOF | 华南理工大学 | 2024-06-13 | — | — | WO | disclosed |
| CN-115785185-A | Bile acid-metronidazole conjugate and application thereof | 华南理工大学 | 2023-03-14 | — | — | CN | disclosed |
| CN-115175926-A | Activatable cytokine polypeptides and methods of use thereof | 狼人治疗公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-113219045-B | Composite nano material, preparation method and application thereof | 山东农业大学 | 2022-03-29 | — | — | CN | disclosed |
| CN-113219045-A | Composite nano material, preparation method and application thereof | 山东农业大学 | 2021-08-06 | — | — | CN | disclosed |
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-07-22 | — | — | US | disclosed |
| EP-3810137-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-04-28 | — | — | EP | disclosed |
| US-20130095051-A1 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA | GALDERMA S.A. (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20120087876-A1 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA | GALDERMA, S.A. (CH) | 2012-04-12 | — | — | US | disclosed |
| US-20110274631-A1 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA | GALDERMA S.A. (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110217357-A1 | METHOD FOR SOLUBILIZING METRONIDAZOLE | GALDERMA S.A. (CH) | 2011-09-08 | — | — | US | disclosed |
| US-7981916-B2 | Aqueous solutions made with niacinamide and multiple glycolic cosolvents; cyclodextrin and surfactant free; rosacea; nonirritating, nonallergenic | GALDERMA S.A. (CH) | 2011-07-19 | — | — | US | disclosed |
| US-20110033395-A1 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA | GALDERMA, S.A. (CH) | 2011-02-10 | — | — | US | disclosed |
| US-20100048645-A1 | Solubilizing of metronidazole | Galderma Holding SA (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20090163568-A1 | AVERMECTIN/METRONIDAZOLE COMPOSITIONS FOR TREATING AFFLICTIONS OF THE SKIN, E.G., ROSACEA | GALDERMA S.A. (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20080194664-A1 | Avermectin/metronidazole compositions for treating afflictions of the skin, e.g., rosacea | GALDERMA S.A. (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20080161375-A1 | Solubilizing of metronidazole | GALDERMA S.A. (CH) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | PHB1, COX5B, CYP3A5 | LMNA 3271/4885ALDH1A1 3471/4885MAPK1 3643/4885 |
| US-12171748-B2 | Nitroimidazole formulations | PHB1, COX5B, CYP3A5 | LMNA 3271/4885ALDH1A1 3471/4885MAPK1 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.